The Women’s Tennis Association (WTA) has announced a new partnership with Masimo, introducing the Masimo MightySat™ to enhance athlete wellness and performance monitoring on the women’s tennis circuit. The WTA’s Sport Sciences and Medicine (SS&M) team will now integrate the MightySat pulse oximeter into their health protocols, providing players with cutting-edge, noninvasive health insights.
MightySat is a fingertip pulse oximeter designed for applications in sports and fitness, offering real-time measurements of oxygen saturation (SpO2), pulse rate (PR), perfusion index (Pi), PVi® (indicating hydration and respiratory factors), and RRp™ (respiration rate based on plethysmographic waveform analysis). Utilizing Masimo’s SET® technology, the device ensures high accuracy in motion and low perfusion conditions, while data can also be tracked through the Masimo Personal Health app for iOS® and Android® devices.
The WTA’s primary health care providers—licensed physical therapists and certified athletic trainers—will utilize MightySat at WTA events to monitor and support players’ overall health and fitness. “This equipment will aid our healthcare providers in assessing player health and allow them to better address the immediate needs of our athletes,” said Kathleen Stroia, SVP of SS&M and Transitions for the WTA.
Masimo CEO Joe Kiani expressed enthusiasm about the collaboration: “We’re thrilled to support the WTA in using our noninvasive technology to make a meaningful impact on women’s tennis. We hope that MightySat’s precise data will empower players to optimize their training and health management.”
While MightySat serves general wellness and fitness, Masimo also offers the MightySat Rx model for medical professionals, expanding applications across both athletic and clinical settings. This partnership marks a step forward in health technology for women’s tennis, promoting player wellness and performance with advanced, real-time insights.